≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Malignant otitis externa

DOID Endpoint Browser PheWeb

H8_EXT_MALIGN

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — H60.2
  • Hospital discharge: ICD-9 — 3801C
  • Cause of death: ICD-10 — H60.2
  • Cause of death: ICD-9 — 3801C

2 out of 7 registries used, show all original rules.

68

4. Check minimum number of events

None

68

5. Include endpoints

None

68

6. Filter based on genotype QC (FinnGen only)

64

Control definitions (FinnGen only)

Control exclude
H8_EXTERNAL

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
H60
Name in latin
Otitis externa [maligna]

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 540 251 283
Only index persons 480 228 252
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 54.45 50.70 57.43
Only index persons 53.03 48.66 56.98

-FinnGen-

Key figures

All Female Male
Number of individuals 64 28 36
Unadjusted period prevalence (%) 0.01 0.01 0.02
Median age at first event (years) 57.63 47.51 65.50

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
68
Matched controls
680
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H60.2
ICD-10 Finland
Malignant otitis externa
+∞
94.8
67
*
H60.9
ICD-10 Finland
Otitis externa, unspecified
22.3
20.0
30
23
H60.8
ICD-10 Finland
Other otitis externa
92.5
18.9
20
*
H60.3
ICD-10 Finland
Other infective otitis externa
39.9
14.8
18
6
DC1AD
NOMESCO Finland
Temporalbone CT
129.1
10.7
11
*
H66.9
ICD-10 Finland
Otitis media, unspecified
12.4
10.0
18
19
H60
ICD-10 Finland
Otitis externa
12.7
9.1
16
16
Z01.1
ICD-10 Finland
Examination of ears and hearing
5.6
8.6
20
47
UDC00
NOMESCO Finland
Ear microscopy
9.1
8.1
17
24
H66.0
ICD-10 Finland
Acute suppurative otitis media
8.3
7.7
17
26
H60.0
ICD-10 Finland
Abscess of external ear
+∞
7.4
7
*
J01MA02
ATC
ciprofloxacin; systemic
3.8
7.0
38
169
H70.1
ICD-10 Finland
Chronic mastoiditis
76.8
6.5
7
*
H72.0
ICD-10 Finland
Central perforation of tympanic membrane
29.7
6.4
8
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Otolaryngology
4 [38004449]
1.7e+00
2.6e+00
—
—
—
3.4e+00
1.9e+00
cases:37.88%
controls:10.15%
cases:31.82%
controls:3.48%
—
—
—
—
—
—
cases:50.00%
controls:3.08%
cases:41.82%
controls:9.47%
25
67
41
593
21
23
45
637
—
—
—
32
20
32
630
23
52
32
497
cefalexin; oral
J01DB01 [21602870]
1.4e+00
1.6e+00
3.0e+00
—
2.6e+00
8.9e-01
8.8e-01
cases:60.61%
controls:28.33%
cases:33.33%
controls:9.24%
cases:21.21%
controls:1.36%
—
—
cases:12.31%
controls:1.06%
cases:21.88%
controls:10.31%
cases:49.09%
controls:28.60%
40
187
26
473
22
61
44
599
14
9
52
651
—
8
7
57
653
14
67
50
583
27
157
28
392
Pharmacy visit
OMOP4822462 [581458]
1.0e+50
2.8e+00
1.3e+00
2.8e+00
9.3e-01
1.5e+00
1.0e+50
cases:100.00%
controls:93.03%
cases:98.48%
controls:79.09%
cases:75.76%
controls:45.76%
cases:25.76%
controls:1.97%
cases:67.69%
controls:45.30%
cases:95.31%
controls:82.00%
cases:100.00%
controls:95.26%
66
614
0
46
65
522
1
138
50
302
16
358
17
13
49
647
44
299
21
361
61
533
3
117
55
523
0
26
Laboratory Visit
OMOP4822461 [32036]
4.0e-02
2.5e-01
1.3e+00
3.3e+00
1.3e+00
2.0e-01
2.3e-01
cases:34.85%
controls:33.94%
cases:34.85%
controls:29.39%
cases:27.27%
controls:8.94%
cases:16.67%
controls:0.76%
cases:26.15%
controls:9.09%
cases:34.38%
controls:30.00%
cases:43.64%
controls:38.07%
23
224
43
436
23
194
43
466
18
59
48
601
11
5
55
655
17
60
48
600
22
195
42
455
24
209
31
340
Outpatient Visit
OP [9202]
8.2e-01
6.3e-01
8.5e-01
—
2.3e+00
1.5e+00
1.8e+00
cases:80.30%
controls:64.24%
cases:59.09%
controls:43.48%
cases:22.73%
controls:11.21%
—
—
cases:52.31%
controls:9.55%
cases:79.69%
controls:46.62%
cases:94.55%
controls:73.59%
53
424
13
236
39
287
27
373
15
74
51
586
—
34
63
31
597
51
303
13
347
52
404
3
145
Case Management Agency
251B00000X [38004193]
2.9e-01
2.5e-01
7.9e-01
3.3e+00
1.1e+00
1.8e-01
7.8e-02
cases:56.06%
controls:48.79%
cases:46.97%
controls:40.91%
cases:28.79%
controls:15.45%
cases:22.73%
controls:1.06%
cases:36.92%
controls:16.21%
cases:46.88%
controls:42.31%
cases:60.00%
controls:58.11%
37
322
29
338
31
270
35
390
19
102
47
558
15
7
51
653
24
107
41
553
30
275
34
375
33
319
22
230
Audiology
64 [38004489]
—
2.4e+00
—
—
—
2.0e+00
1.9e+00
—
—
cases:7.58%
controls:0.76%
—
—
—
—
—
—
cases:9.38%
controls:1.38%
cases:12.73%
controls:2.19%
—
5
5
61
655
—
—
—
6
9
58
641
7
12
48
537
Emergency Room Visit
ER [9203]
5.2e-01
1.0e+00
3.1e+00
1.0e+50
—
9.8e-01
3.7e-01
cases:42.42%
controls:30.45%
cases:27.27%
controls:11.97%
cases:19.70%
controls:1.06%
cases:34.85%
controls:0.00%
—
—
cases:26.56%
controls:12.00%
cases:36.36%
controls:28.23%
28
201
38
459
18
79
48
581
13
7
53
653
23
0
43
660
—
17
78
47
572
20
155
35
394
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-3.8e-02
4.7e-01
2.0e+00
—
1.5e+00
4.8e-01
3.6e-01
cases:19.70%
controls:20.30%
cases:24.24%
controls:16.67%
cases:15.15%
controls:2.42%
—
—
cases:13.85%
controls:3.33%
cases:25.00%
controls:17.08%
cases:30.91%
controls:23.86%
13
134
53
526
16
110
50
550
10
16
56
644
—
9
22
56
638
16
111
48
539
17
131
38
418
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.3e-01
5.1e-01
1.8e+00
—
1.5e+00
5.0e-01
2.5e-01
cases:30.30%
controls:27.73%
cases:31.82%
controls:21.97%
cases:19.70%
controls:3.79%
—
—
cases:16.92%
controls:4.39%
cases:32.81%
controls:22.92%
cases:38.18%
controls:32.42%
20
183
46
477
21
145
45
515
13
25
53
635
—
11
29
54
631
21
149
43
501
21
178
34
371
Home Visit
OMOP4822459 [581476]
5.8e-01
1.1e+00
—
—
2.8e+00
1.3e+00
6.6e-01
cases:7.58%
controls:4.39%
cases:9.09%
controls:3.18%
—
—
—
—
cases:10.77%
controls:0.76%
cases:10.94%
controls:3.23%
cases:9.09%
controls:4.92%
5
29
61
631
6
21
60
639
—
—
7
5
58
655
7
21
57
629
5
27
50
522
Emergency Medicine
93 [38004510]
4.4e-01
7.7e-01
2.7e+00
—
—
1.0e+00
7.5e-01
cases:15.15%
controls:10.30%
cases:13.64%
controls:6.82%
cases:10.61%
controls:0.76%
—
—
—
—
cases:14.06%
controls:5.54%
cases:25.45%
controls:13.84%
10
68
56
592
9
45
57
615
7
5
59
655
—
—
9
36
55
614
14
76
41
473
Monitoring the use of the aid
R5140 [2001310249]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:0.91%
—
—
—
—
—
—
6
5
49
544
hydrocortisone and antiinfectives
S02CA03 [21605175]
—
—
1.0e+50
—
—
—
2.6e+00
—
—
—
—
cases:7.58%
controls:0.00%
—
—
—
—
—
—
cases:16.36%
controls:1.46%
—
—
5
0
61
660
—
—
—
9
8
46
541
hydrocortisone and antiinfectives
S03CA04 [21605208]
—
—
1.0e+50
—
—
—
2.6e+00
—
—
—
—
cases:7.58%
controls:0.00%
—
—
—
—
—
—
cases:16.36%
controls:1.46%
—
—
5
0
61
660
—
—
—
9
8
46
541
General Practice
1 [38004446]
8.6e-01
—
—
—
—
1.4e+00
1.2e+00
cases:24.24%
controls:11.97%
—
—
—
—
—
—
—
—
cases:17.19%
controls:5.08%
cases:25.45%
controls:9.65%
16
79
50
581
—
—
—
—
11
33
53
617
14
53
41
496
Internal Medicine
11 [38004456]
8.5e-01
7.1e-01
2.4e+00
—
—
6.2e-01
-5.8e-02
cases:36.36%
controls:19.70%
cases:16.67%
controls:8.94%
cases:10.61%
controls:1.06%
—
—
—
—
cases:17.19%
controls:10.00%
cases:20.00%
controls:20.95%
24
130
42
530
11
59
55
601
7
7
59
653
—
—
11
65
53
585
11
115
44
434
INR in Blood by Coagulation assay
34714-6 [3032080]
1.8e-01
8.4e-01
—
—
2.4e+00
1.2e+00
8.0e-01
cases:9.09%
controls:7.73%
cases:10.61%
controls:4.85%
—
—
—
—
cases:7.69%
controls:0.76%
cases:12.50%
controls:4.15%
cases:14.55%
controls:7.10%
6
51
60
609
7
32
59
628
—
—
5
5
60
655
8
27
56
623
8
39
47
510
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
2.4e+00
—
—
—
—
—
—
cases:9.09%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
60
654
—
—
—
—
—
—
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
2.4e+00
—
—
—
—
—
—
cases:7.58%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
61
655
—
—
—
—
—
—
boric acid
S02AA03 [21605149]
2.4e+00
—
—
—
—
—
—
cases:7.58%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
61
655
—
—
—
—
—
—
Inpatient Hospital
21 [8717]
4.6e-01
3.5e-01
2.3e+00
1.0e+50
—
6.2e-01
8.1e-01
cases:43.94%
controls:33.03%
cases:13.64%
controls:10.00%
cases:12.12%
controls:1.36%
cases:10.61%
controls:0.00%
—
—
cases:17.19%
controls:10.00%
cases:43.64%
controls:25.68%
29
218
37
442
9
66
57
594
8
9
58
651
7
0
59
660
—
11
65
53
585
24
141
31
408
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
1.9e+00
—
—
1.0e+50
—
2.2e+00
—
cases:7.58%
controls:1.21%
—
—
—
—
cases:9.09%
controls:0.00%
—
—
cases:9.38%
controls:1.08%
—
—
5
8
61
652
—
—
6
0
60
660
—
6
7
58
643
—
Otitis externa, unspecified
H60.9 [45605727]
—
1.0e+50
—
—
1.0e+50
—
2.2e+00
—
—
cases:10.61%
controls:0.00%
—
—
—
—
cases:9.23%
controls:0.00%
—
—
cases:10.91%
controls:1.28%
—
7
0
59
660
—
—
6
0
59
660
—
6
7
49
542
Normoblasts [#/volume] in Blood
715-3 [3021589]
8.1e-01
1.2e+00
—
—
2.1e+00
9.7e-01
6.5e-01
cases:12.12%
controls:5.76%
cases:12.12%
controls:4.09%
—
—
—
—
cases:9.23%
controls:1.21%
cases:14.06%
controls:5.85%
cases:18.18%
controls:10.38%
8
38
58
622
8
27
58
633
—
—
6
8
59
652
9
38
55
612
10
57
45
492
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
5.1e-01
1.1e+00
—
—
—
1.9e+00
9.4e-01
cases:10.61%
controls:6.67%
cases:7.58%
controls:2.58%
—
—
—
—
—
—
cases:10.94%
controls:1.85%
cases:10.91%
controls:4.55%
7
44
59
616
5
17
61
643
—
—
—
7
12
57
638
6
25
49
524
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.5e-01
3.7e-01
1.5e+00
—
1.9e+00
6.3e-01
4.1e-01
cases:24.24%
controls:20.00%
cases:19.70%
controls:14.55%
cases:12.12%
controls:2.88%
—
—
cases:16.92%
controls:3.03%
cases:21.88%
controls:12.92%
cases:34.55%
controls:25.87%
16
132
50
528
13
96
53
564
8
19
58
641
—
11
20
54
640
14
84
50
566
19
142
36
407
CBC panel - Blood by Automated count
58410-2 [40761511]
1.8e-01
2.8e-01
1.2e+00
—
1.9e+00
2.0e-01
2.0e-01
cases:28.79%
controls:25.15%
cases:21.21%
controls:16.97%
cases:9.09%
controls:2.88%
—
—
cases:15.38%
controls:2.73%
cases:18.75%
controls:15.85%
cases:30.91%
controls:26.78%
19
166
47
494
14
112
52
548
6
19
60
641
—
10
18
55
642
12
103
52
547
17
147
38
402
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
5.2e-01
6.3e-01
1.7e+00
—
1.3e+00
5.0e-01
8.4e-01
cases:37.88%
controls:26.52%
cases:25.76%
controls:15.61%
cases:13.64%
controls:2.73%
—
—
cases:10.77%
controls:3.18%
cases:20.31%
controls:13.38%
cases:49.09%
controls:29.33%
25
175
41
485
17
103
49
557
9
18
57
642
—
7
21
58
639
13
87
51
563
27
161
28
388
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
9.4e-02
3.0e-01
1.4e+00
—
1.6e+00
4.3e-01
1.1e-01
cases:18.18%
controls:16.82%
cases:18.18%
controls:14.09%
cases:10.61%
controls:2.73%
—
—
cases:13.85%
controls:3.03%
cases:21.88%
controls:15.38%
cases:23.64%
controls:21.68%
12
111
54
549
12
93
54
567
7
18
59
642
—
9
20
56
640
14
100
50
550
13
119
42
430
Leukocytes [#/volume] in Blood
26464-8 [3010813]
9.2e-02
3.3e-01
1.2e+00
—
1.6e+00
3.1e-01
2.4e-01
cases:31.82%
controls:29.85%
cases:30.30%
controls:23.79%
cases:15.15%
controls:5.00%
—
—
cases:21.54%
controls:5.15%
cases:31.25%
controls:24.92%
cases:40.00%
controls:34.43%
21
197
45
463
20
157
46
503
10
33
56
627
—
14
34
51
626
20
162
44
488
22
189
33
360
Platelets [#/volume] in Blood
26515-7 [3007461]
1.0e-01
3.3e-01
1.2e+00
—
1.6e+00
3.1e-01
2.4e-01
cases:31.82%
controls:29.70%
cases:30.30%
controls:23.79%
cases:15.15%
controls:5.00%
—
—
cases:21.54%
controls:5.15%
cases:31.25%
controls:25.08%
cases:40.00%
controls:34.43%
21
196
45
464
20
157
46
503
10
33
56
627
—
14
34
51
626
20
163
44
487
22
189
33
360
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
9.2e-02
3.3e-01
1.2e+00
—
1.6e+00
3.1e-01
2.4e-01
cases:31.82%
controls:29.85%
cases:30.30%
controls:23.79%
cases:15.15%
controls:5.00%
—
—
cases:21.54%
controls:5.15%
cases:31.25%
controls:24.92%
cases:40.00%
controls:34.43%
21
197
45
463
20
157
46
503
10
33
56
627
—
14
34
51
626
20
162
44
488
22
189
33
360
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
9.2e-02
3.3e-01
1.2e+00
—
1.6e+00
3.1e-01
2.4e-01
cases:31.82%
controls:29.85%
cases:30.30%
controls:23.79%
cases:15.15%
controls:5.00%
—
—
cases:21.54%
controls:5.15%
cases:31.25%
controls:24.92%
cases:40.00%
controls:34.43%
21
197
45
463
20
157
46
503
10
33
56
627
—
14
34
51
626
20
162
44
488
22
189
33
360
MCH [Entitic mass]
28539-5 [3035941]
9.2e-02
3.3e-01
1.2e+00
—
1.6e+00
3.1e-01
2.4e-01
cases:31.82%
controls:29.85%
cases:30.30%
controls:23.79%
cases:15.15%
controls:5.00%
—
—
cases:21.54%
controls:5.15%
cases:31.25%
controls:24.92%
cases:40.00%
controls:34.43%
21
197
45
463
20
157
46
503
10
33
56
627
—
14
34
51
626
20
162
44
488
22
189
33
360
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
8.5e-02
4.0e-01
1.2e+00
—
1.6e+00
3.1e-01
2.4e-01
cases:31.82%
controls:30.00%
cases:31.82%
controls:23.79%
cases:15.15%
controls:5.00%
—
—
cases:21.54%
controls:5.15%
cases:31.25%
controls:25.08%
cases:40.00%
controls:34.43%
21
198
45
462
21
157
45
503
10
33
56
627
—
14
34
51
626
20
163
44
487
22
189
33
360
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
9.2e-02
3.3e-01
1.2e+00
—
1.6e+00
3.0e-01
2.4e-01
cases:31.82%
controls:29.85%
cases:30.30%
controls:23.79%
cases:15.15%
controls:5.00%
—
—
cases:21.54%
controls:5.15%
cases:31.25%
controls:25.23%
cases:40.00%
controls:34.43%
21
197
45
463
20
157
46
503
10
33
56
627
—
14
34
51
626
20
164
44
486
22
189
33
360
Outpatient Hospital
22 [8756]
3.9e-01
9.1e-01
—
—
—
1.4e+00
6.7e-01
cases:33.33%
controls:25.30%
cases:15.15%
controls:6.67%
—
—
—
—
—
—
cases:18.75%
controls:5.38%
cases:30.91%
controls:18.58%
22
167
44
493
10
44
56
616
—
—
—
12
35
52
615
17
102
38
447
amoxicillin; oral, parenteral
J01CA04 [21602823]
4.7e-01
1.3e+00
—
—
—
1.1e+00
8.6e-01
cases:31.82%
controls:22.58%
cases:19.70%
controls:6.06%
—
—
—
—
—
—
cases:15.63%
controls:5.85%
cases:38.18%
controls:20.77%
21
149
45
511
13
40
53
620
—
—
—
10
38
54
612
21
114
34
435
betamethasone
A07EA04 [21600656]
6.6e-01
—
—
—
—
—
1.3e+00
cases:10.61%
controls:5.76%
—
—
—
—
—
—
—
—
—
—
cases:21.82%
controls:6.92%
7
38
59
622
—
—
—
—
—
12
38
43
511
betamethasone
C05AA05 [21601610]
6.6e-01
—
—
—
—
—
1.3e+00
cases:10.61%
controls:5.76%
—
—
—
—
—
—
—
—
—
—
cases:21.82%
controls:6.92%
7
38
59
622
—
—
—
—
—
12
38
43
511
betamethasone
D07AC01 [21602120]
6.6e-01
—
—
—
—
—
1.3e+00
cases:10.61%
controls:5.76%
—
—
—
—
—
—
—
—
—
—
cases:21.82%
controls:6.92%
7
38
59
622
—
—
—
—
—
12
38
43
511
betamethasone
S02BA07 [21605169]
6.6e-01
—
—
—
—
—
1.3e+00
cases:10.61%
controls:5.76%
—
—
—
—
—
—
—
—
—
—
cases:21.82%
controls:6.92%
7
38
59
622
—
—
—
—
—
12
38
43
511
Periapical abscess without sinus
K04.7 [45586692]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Vertigo/dizziness
N17 [2002000728]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
phenoxymethylpenicillin; oral
J01CE02 [21602842]
—
—
—
—
—
—
7.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:21.82%
controls:11.48%
—
—
—
—
—
—
12
63
43
486
Acute appendicitis, unspecified
K35.9 [45557651]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.37%
—
0
6
66
654
—
—
—
—
0
13
55
536
Basic examination of mouth
SAA02 [2001310275]
-2.7e-01
—
—
—
—
—
3.9e-01
cases:10.61%
controls:13.48%
—
—
—
—
—
—
—
—
—
—
cases:18.18%
controls:13.11%
7
89
59
571
—
—
—
—
—
10
72
45
477
Glaucoma suspect
H40.0 [45567051]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.82%
0
8
66
652
—
—
—
—
—
0
10
55
539
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
—
9.6e-01
—
—
—
—
4.1e-01
—
—
cases:7.58%
controls:3.03%
—
—
—
—
—
—
—
—
cases:9.09%
controls:6.19%
—
5
20
61
640
—
—
—
—
5
34
50
515
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
7.7e-01
—
—
—
—
—
—
cases:7.58%
controls:3.64%
—
—
—
—
—
—
—
—
—
—
—
—
5
24
61
636
—
—
—
—
—
—
Right side
ZXA00 [2001311346]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.10%
—
—
—
—
—
—
0
17
55
532
Issue of medical certificate
Z02.7 [45537613]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
1.0e+00
—
—
—
—
—
4.9e-01
cases:12.12%
controls:4.70%
—
—
—
—
—
—
—
—
—
—
cases:12.73%
controls:8.20%
8
31
58
629
—
—
—
—
—
7
45
48
504
Other health check-up
SPAT1370 [2001700471]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
—
Unspecified dementia
F03 [45566772]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Production of copy from X-ray picture
XX9AW [2001311036]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
0
6
66
654
—
—
—
—
0
8
55
541
EKG study
11524-6 [3013512]
—
—
—
—
—
—
5.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.73%
controls:7.65%
—
—
—
—
—
—
7
42
48
507
alendronic acid; oral
M05BA04 [21604152]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
0
6
66
654
—
—
—
—
—
0
8
55
541
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.06%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:0.77%
cases:0.00%
controls:0.91%
0
7
66
653
0
6
66
654
—
—
—
0
5
64
645
0
5
55
544
Chest pain, unspecified
R07.4 [45558450]
1.2e+00
—
—
—
—
—
—
cases:9.09%
controls:3.03%
—
—
—
—
—
—
—
—
—
—
—
—
6
20
60
640
—
—
—
—
—
—
Predominantly allergic asthma
J45.0 [45557624]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
—
Presence of electronic cardiac devices
Z95.0 [45571406]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
66
653
—
—
—
—
—
—
Acute bronchitis
J20 [45581849]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
ethylmorphine; oral
R05DA01 [21603397]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
0
6
64
644
—
diclofenac
D11AX18 [21602355]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
ranitidine bismuth citrate; oral
A02BA07 [21600088]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
0
5
66
655
—
—
—
—
0
10
55
539
covid-19, RNA-based vaccine
J07BN01 [954934]
2.2e-01
2.0e-01
-1.0e+50
—
—
3.9e-02
-3.6e-02
cases:12.12%
controls:10.00%
cases:9.09%
controls:7.58%
cases:0.00%
controls:0.91%
—
—
—
—
cases:7.81%
controls:7.54%
cases:20.00%
controls:20.58%
8
66
58
594
6
50
60
610
0
6
66
654
—
—
5
49
59
601
11
113
44
436
Catheterisation of bladder
TKC20 [2001306020]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
—
Operative extraction of tooth
EBA10 [2001301925]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
0
7
55
542
felodipine; oral
C08CA02 [21601748]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.85%
cases:0.00%
controls:1.64%
—
—
—
—
—
0
12
64
638
0
9
55
540
Laser discission of secondary cataract
CJB10 [2001301313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
—
Leukocytes [Presence] in Urine
33052-2 [3045414]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
cases:0.00%
controls:1.82%
—
—
—
—
—
0
5
64
645
0
10
55
539
furosemide; oral, parenteral
C03CA01 [21601518]
6.1e-01
7.8e-01
1.6e+00
—
—
7.2e-01
8.6e-01
cases:10.61%
controls:6.06%
cases:9.09%
controls:4.39%
cases:7.58%
controls:1.67%
—
—
—
—
cases:9.38%
controls:4.77%
cases:12.73%
controls:5.83%
7
40
59
620
6
29
60
631
5
11
61
649
—
—
6
31
58
619
7
32
48
517
scopolamine; oral, parenteral
N05CM05 [21604666]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
trimethoprim; oral, parenteral
J01EA01 [21602931]
4.4e-01
—
—
—
—
—
—
cases:9.09%
controls:6.06%
—
—
—
—
—
—
—
—
—
—
—
—
6
40
60
620
—
—
—
—
—
—
Type 1 diabetes mellitus, With ketoacidosis
E10.1 [45542735]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
—
Medical Oncology
90 [38004507]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
clidinium and psycholeptics
A03CA02 [21600204]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
—
hydrocortisone
C05AA01 [21601608]
1.2e+00
—
—
—
—
—
1.2e+00
cases:16.67%
controls:5.91%
—
—
—
—
—
—
—
—
—
—
cases:20.00%
controls:6.74%
11
39
55
621
—
—
—
—
—
11
37
44
512
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
4.2e-01
-2.3e-02
—
—
—
4.9e-01
3.0e-01
cases:31.82%
controls:23.48%
cases:15.15%
controls:15.45%
—
—
—
—
—
—
cases:25.00%
controls:16.92%
cases:34.55%
controls:28.05%
21
155
45
505
10
102
56
558
—
—
—
16
110
48
540
19
154
36
395
letrozole; oral
L02BG04 [21603842]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
0
7
64
643
—
Inpatient Visit
IP [9201]
8.9e-01
1.2e+00
—
—
—
—
—
cases:9.09%
controls:3.94%
cases:7.58%
controls:2.42%
—
—
—
—
—
—
—
—
—
—
6
26
60
634
5
16
61
644
—
—
—
—
—
other preparations, combinations; ointment
C05AX03 [21601631]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:2.00%
—
—
—
—
—
—
6
11
49
538
Hyperlipidaemia, unspecified
E78.5 [45537986]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Medical abortion, complete or unspecified, without complication
O04.9 [45543909]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
—
Hematology
82 [38004501]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
pantoprazole; oral, parenteral
A02BC02 [21600097]
3.8e-01
7.0e-01
—
—
—
6.2e-01
7.5e-01
cases:15.15%
controls:10.91%
cases:13.64%
controls:7.27%
—
—
—
—
—
—
cases:15.63%
controls:9.08%
cases:25.45%
controls:13.84%
10
72
56
588
9
48
57
612
—
—
—
10
59
54
591
14
76
41
473
metronidazole; oral, rectal
P01AB01 [21604857]
3.6e-01
—
—
—
—
—
—
cases:9.09%
controls:6.52%
—
—
—
—
—
—
—
—
—
—
—
—
6
43
60
617
—
—
—
—
—
—
Fever
A03 [2002000144]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
escitalopram; oral
N06AB10 [21604718]
—
—
—
—
—
—
7.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:4.37%
—
—
—
—
—
—
5
24
50
525
Calculus of gallbladder without cholecystitis
K80.2 [45552951]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Medication, disinfection of root canals
SGC00 [2001310392]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.37%
0
5
66
655
—
—
—
—
—
0
13
55
536
ketoprofen, combinations
M01AE53 [21603985]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
zopiclone; oral
N05CF01 [21604654]
1.6e-01
7.3e-01
—
—
—
—
3.0e-01
cases:7.58%
controls:6.52%
cases:7.58%
controls:3.79%
—
—
—
—
—
—
—
—
cases:9.09%
controls:6.92%
5
43
61
617
5
25
61
635
—
—
—
—
5
38
50
511
Angina pectoris
I20 [45572078]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
—
fluconazole; oral, parenteral
J02AC01 [21603080]
—
1.4e+00
—
—
—
—
8.2e-01
—
—
cases:7.58%
controls:1.97%
—
—
—
—
—
—
—
—
cases:12.73%
controls:6.01%
—
5
13
61
647
—
—
—
—
7
33
48
516
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
3.2e-01
—
—
—
—
5.6e-01
3.8e-01
cases:15.15%
controls:11.52%
—
—
—
—
—
—
—
—
cases:12.50%
controls:7.54%
cases:16.36%
controls:11.84%
10
76
56
584
—
—
—
—
8
49
56
601
9
65
46
484
Other specified counselling
Z71.8 [45581061]
1.0e+00
—
—
—
—
—
9.7e-01
cases:7.58%
controls:2.88%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:3.64%
5
19
61
641
—
—
—
—
—
5
20
50
529
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
—
1.1e+00
—
—
—
—
2.7e-01
—
—
cases:9.09%
controls:3.18%
—
—
—
—
—
—
—
—
cases:12.73%
controls:10.02%
—
6
21
60
639
—
—
—
—
7
55
48
494
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
4.0e-01
7.8e-01
—
—
—
8.3e-01
5.3e-01
cases:12.12%
controls:8.48%
cases:9.09%
controls:4.39%
—
—
—
—
—
—
cases:9.38%
controls:4.31%
cases:14.55%
controls:9.11%
8
56
58
604
6
29
60
631
—
—
—
6
28
58
622
8
50
47
499
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
0
6
66
654
—
—
—
—
—
0
5
55
544
Gastroenterology
10 [38004455]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
0
10
66
650
—
—
—
0
10
64
640
—
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
66
648
—
—
—
—
—
—
scopolamine, combinations
A04AD51 [21600507]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Leukocytes [#/volume] in Urine
30405-5 [3018095]
—
—
—
—
—
—
6.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:5.83%
—
—
—
—
—
—
6
32
49
517
scopolamine
A04AD01 [21600499]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
0
11
64
639
—
Restricted health certificate
SPAT1283 [2001700384]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
0
9
55
540
Nursing episode
950 [44777714]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
66
646
—
—
—
—
—
—
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.97%
cases:0.00%
controls:0.76%
—
—
—
—
—
—
cases:0.00%
controls:0.77%
cases:0.00%
controls:2.37%
0
13
66
647
0
5
66
655
—
—
—
0
5
64
645
0
13
55
536
Emergency Room and Inpatient Visit
ERIP [262]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:14.55%
controls:5.10%
—
—
—
—
—
—
8
28
47
521
Cells panel - Urine sediment
58434-2 [40761535]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
0
6
66
654
—
—
—
—
0
5
55
544
Coloscopy
UJF32 [2001305029]
1.0e+00
—
—
—
—
—
—
cases:7.58%
controls:2.88%
—
—
—
—
—
—
—
—
—
—
—
—
5
19
61
641
—
—
—
—
—
—
Check up of cardiac pacemaker
XFP20 [2001303367]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
-1.4e-02
—
—
—
—
—
3.2e-01
cases:12.12%
controls:12.27%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:6.74%
8
81
58
579
—
—
—
—
—
5
37
50
512
Heartburn
R12 [45539318]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
—
—
—
0
8
55
541
Other senile cataract
H25.8 [45605644]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
66
653
—
—
—
—
—
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
6.7e-01
—
—
—
—
—
—
cases:9.09%
controls:4.85%
—
—
—
—
—
—
—
—
—
—
—
—
6
32
60
628
—
—
—
—
—
—
No disease
A97 [2002000230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
—
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
9.8e-01
1.3e+00
—
—
-1.0e+50
—
1.1e+00
cases:10.61%
controls:4.24%
cases:9.09%
controls:2.58%
—
—
—
—
cases:0.00%
controls:0.91%
—
—
cases:9.09%
controls:3.28%
7
28
59
632
6
17
60
643
—
—
0
6
65
654
—
5
18
50
531
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
1.4e-01
-1.0e+50
—
—
—
—
-1.0e+50
cases:9.09%
controls:8.03%
cases:0.00%
controls:1.97%
—
—
—
—
—
—
—
—
cases:0.00%
controls:6.38%
6
53
60
607
0
13
66
647
—
—
—
—
0
35
55
514
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
7.4e-01
—
—
—
-1.0e+50
—
5.3e-01
cases:9.09%
controls:4.55%
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
cases:10.91%
controls:6.74%
6
30
60
630
—
—
—
0
5
65
655
—
6
37
49
512
pivmecillinam; oral
J01CA08 [21602827]
6.1e-01
-1.0e+50
—
—
—
—
5.7e-01
cases:10.61%
controls:6.06%
cases:0.00%
controls:1.67%
—
—
—
—
—
—
—
—
cases:14.55%
controls:8.74%
7
40
59
620
0
11
66
649
—
—
—
—
8
48
47
501
Foot/toe symptom/complaint
L17 [2002000641]
1.2e+00
—
—
—
—
—
7.5e-01
cases:7.58%
controls:2.42%
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:5.46%
5
16
61
644
—
—
—
—
—
6
30
49
519
estriol; oral, parenteral, vaginal
G03CA04 [21602518]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
-1.0e-01
—
—
—
—
—
—
cases:7.58%
controls:8.33%
—
—
—
—
—
—
—
—
—
—
—
—
5
55
61
605
—
—
—
—
—
—
hydrocortisone butyrate
D07AB02 [21602106]
1.2e+00
—
—
—
—
—
1.2e+00
cases:16.67%
controls:5.91%
—
—
—
—
—
—
—
—
—
—
cases:20.00%
controls:6.74%
11
39
55
621
—
—
—
—
—
11
37
44
512
Knee symptom/complaint
L15 [2002000639]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
ketotifen
S01GX08 [21605092]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
brimonidine
S01GA07 [947915]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.76%
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
0
6
66
654
0
5
66
655
—
—
—
0
5
64
645
—
montelukast; oral
R03DC03 [21603356]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
One-surface restoration
SFA10 [2001310358]
5.1e-01
—
—
—
—
4.3e-01
1.0e-01
cases:15.15%
controls:9.70%
—
—
—
—
—
—
—
—
cases:7.81%
controls:5.23%
cases:12.73%
controls:11.66%
10
64
56
596
—
—
—
—
5
34
59
616
7
64
48
485
Prostate cancer
116 [2001600116]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Atherosclerotic heart disease
I25.1 [45596196]
9.5e-01
—
—
—
—
—
—
cases:10.61%
controls:4.39%
—
—
—
—
—
—
—
—
—
—
—
—
7
29
59
631
—
—
—
—
—
—
levonorgestrel
G03AC03 [21602499]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
0
5
66
655
—
—
—
—
—
0
9
55
540
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
acetylsalicylic acid; oral
B01AC06 [21600991]
1.5e+00
—
—
—
—
—
—
cases:9.09%
controls:2.27%
—
—
—
—
—
—
—
—
—
—
—
—
6
15
60
645
—
—
—
—
—
—
fluocortolone
C05AA08 [21601612]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Endocrinology
46 [38004485]
1.0e+00
—
—
—
—
—
—
cases:7.58%
controls:2.88%
—
—
—
—
—
—
—
—
—
—
—
—
5
19
61
641
—
—
—
—
—
—
Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
66
653
—
—
—
—
—
—
doxepin; oral, parenteral
N06AA12 [21604699]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Standard cardiac ultrasound examination
FM1AE [2001303278]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.64%
—
—
—
—
—
—
0
20
55
529
Adenocarcinoma, NOS, of prostate gland
8140/3-C61.9 [44499685]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
66
653
—
—
—
—
—
—
apixaban; oral
B01AF02 [43534762]
-1.0e+50
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.67%
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
0
11
66
649
—
—
—
0
10
65
650
—
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.4e+00
—
—
—
—
—
—
cases:7.58%
controls:1.97%
—
—
—
—
—
—
—
—
—
—
—
—
5
13
61
647
—
—
—
—
—
—
prednisolone
S01BA04 [21603621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
66
651
—
—
—
—
—
—
Fibromyalgia
M79.7 [45553272]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
ispaghula (psylla seeds); oral
A06AC01 [21600555]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:3.10%
—
—
—
—
—
—
6
17
49
532
naproxen; oral, rectal
M01AE02 [21603968]
3.4e-01
—
—
—
—
—
6.7e-01
cases:9.09%
controls:6.67%
—
—
—
—
—
—
—
—
—
—
cases:12.73%
controls:6.92%
6
44
60
616
—
—
—
—
—
7
38
48
511
No procedures
SPAT1301 [2001700402]
8.5e-01
—
—
—
—
—
1.3e+00
cases:9.09%
controls:4.09%
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:3.10%
6
27
60
633
—
—
—
—
—
6
17
49
532
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:2.27%
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
0
15
66
645
—
—
—
0
10
64
640
—
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:3.33%
—
—
—
—
—
—
cases:0.00%
controls:3.08%
—
—
—
0
22
66
638
—
—
—
0
20
64
630
—
ibuprofen
R02AX02 [1588667]
4.1e-01
7.7e-01
1.2e+00
—
—
3.5e-01
4.5e-01
cases:39.39%
controls:30.15%
cases:22.73%
controls:11.97%
cases:7.58%
controls:2.42%
—
—
—
—
cases:15.63%
controls:11.54%
cases:41.82%
controls:31.51%
26
199
40
461
15
79
51
581
5
16
61
644
—
—
10
75
54
575
23
173
32
376
Other angina pectoris stenosed coronary artery
I20.81 [2000502397]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.37%
—
—
—
—
—
—
0
13
55
536
hydrocortisone aceponate
D07AC16 [21602135]
1.2e+00
—
—
—
—
—
1.2e+00
cases:16.67%
controls:5.91%
—
—
—
—
—
—
—
—
—
—
cases:20.00%
controls:6.74%
11
39
55
621
—
—
—
—
—
11
37
44
512
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
351 [2001600312]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
0
14
66
646
—
—
—
—
—
0
7
55
542
Other otitis externa
H60.8 [45567109]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:10.94%
controls:0.00%
—
—
—
—
—
—
—
7
0
57
650
—
Cancer Ag 125 [Units/volume] in Serum or Plasma
10334-1 [3037551]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Bilateral
ZXA10 [2001311348]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
0
5
64
645
—
trimipramine; oral, parenteral
N06AA06 [21604693]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Achilles tendinitis
M76.6 [45596682]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
cromoglicic acid
S01GX01 [21605085]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.10%
—
—
—
—
—
—
0
17
55
532
Other administrative function
SPAT1281 [2001700382]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
chondroitin sulfate
M01AX25 [21604013]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
—
—
—
0
8
55
541
Office Visit
OMOP4822458 [581477]
5.7e-01
8.6e-01
—
—
—
—
9.7e-01
cases:13.64%
controls:8.18%
cases:7.58%
controls:3.33%
—
—
—
—
—
—
—
—
cases:16.36%
controls:6.92%
9
54
57
606
5
22
61
638
—
—
—
—
9
38
46
511
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
piroxicam; ointment
M02AA07 [21604043]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
0
7
64
643
—
chloramphenicol
D10AF03 [21602307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
atorvastatin; oral
C10AA05 [21601860]
3.2e-01
1.2e-01
—
—
—
—
6.5e-02
cases:12.12%
controls:9.09%
cases:9.09%
controls:8.18%
—
—
—
—
—
—
—
—
cases:12.73%
controls:12.02%
8
60
58
600
6
54
60
606
—
—
—
—
7
66
48
483
insulin lispro; parenteral
A10AD04 [21600732]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
0
5
65
655
—
—
colecalciferol; oral
A11CC05 [21600820]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
finasteride; oral
G04CB01 [21602675]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
290 [2001600222]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
66
643
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.1e+00
9.7e-01
—
—
—
1.2e+00
5.5e-01
cases:15.15%
controls:5.45%
cases:9.09%
controls:3.64%
—
—
—
—
—
—
cases:14.06%
controls:4.77%
cases:14.55%
controls:8.93%
10
36
56
624
6
24
60
636
—
—
—
9
31
55
619
8
49
47
500
Monocytes [#/volume] in Blood
26484-6 [3001604]
3.5e-01
8.9e-01
—
—
—
8.3e-01
6.2e-01
cases:10.61%
controls:7.73%
cases:9.09%
controls:3.94%
—
—
—
—
—
—
cases:9.38%
controls:4.31%
cases:14.55%
controls:8.38%
7
51
59
609
6
26
60
634
—
—
—
6
28
58
622
8
46
47
503
Pulp capping
SGC10 [2001310393]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
—
insulin aspart; parenteral
A10AB05 [21600719]
1.0e+00
—
—
—
—
—
—
cases:7.58%
controls:2.88%
—
—
—
—
—
—
—
—
—
—
—
—
5
19
61
641
—
—
—
—
—
—
alprazolam; oral
N05BA12 [21604577]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.06%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
0
7
66
653
0
6
66
654
—
—
—
0
6
64
644
—
Alzheimer disease with late onset
G30.1 [45552521]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Feeling depressed
P03 [2002000800]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
methotrexate; oral, parenteral
L04AX03 [21603929]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
66
649
—
—
—
—
—
—
Other disorders of vitreous body
H43.8 [45533329]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
General medical examination
Z00.0 [45585791]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:0.00%
controls:2.19%
—
—
—
—
—
0
6
64
644
0
12
55
537
Telephone prescription or other care instructions
WZB00 [2001310884]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
0
6
64
644
—
hydroxocobalamin
V03AB33 [21605256]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
0
6
66
654
0
5
66
655
—
—
—
—
—
Lumbar spine X-ray examination with flexion
NA3EA [2001307044]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
12 lead EKG panel
34534-8 [3044889]
4.7e-01
6.1e-01
—
—
—
7.2e-01
2.9e-01
cases:21.21%
controls:14.39%
cases:12.12%
controls:6.97%
—
—
—
—
—
—
cases:14.06%
controls:7.38%
cases:16.36%
controls:12.75%
14
95
52
565
8
46
58
614
—
—
—
9
48
55
602
9
70
46
479
chloramphenicol
S02AA01 [21605147]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Day surgery
ZXD20 [2001311388]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.00%
0
12
66
648
—
—
—
—
—
0
11
55
538
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
4.4e-01
9.3e-01
—
—
—
7.1e-01
6.4e-01
cases:10.61%
controls:7.12%
cases:9.09%
controls:3.79%
—
—
—
—
—
—
cases:7.81%
controls:4.00%
cases:14.55%
controls:8.20%
7
47
59
613
6
25
60
635
—
—
—
5
26
59
624
8
45
47
504
Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.19%
0
6
66
654
0
6
66
654
—
—
—
—
0
12
55
537
dexamethasone
D10AA03 [21602286]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
0
7
55
542
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
cases:0.00%
controls:0.91%
—
—
—
—
—
0
5
64
645
0
5
55
544
mometasone; nasal
R01AD09 [21605051]
1.1e+00
—
—
—
-1.0e+50
1.0e+00
9.0e-01
cases:16.67%
controls:6.52%
—
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:7.81%
controls:2.92%
cases:21.82%
controls:10.20%
11
43
55
617
—
—
—
0
6
65
654
5
19
59
631
12
56
43
493
Intraoral radiographic dental examination
EB1AA [2001301903]
3.2e-02
—
—
—
—
—
1.6e-01
cases:10.61%
controls:10.30%
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:9.47%
7
68
59
592
—
—
—
—
—
6
52
49
497
Catheterization of the left side of the heart
AP1 [2000200175]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
—
0
9
64
641
—
Ultrasound measurement of residual urine
KC1EE [2001305918]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
0
7
66
653
—
—
—
0
6
64
644
—
Functional diarrhoea
K59.1 [45543327]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Handing over of treatment supplies
SPAT1262 [2001700363]
1.3e+00
—
—
—
—
—
—
cases:9.09%
controls:2.58%
—
—
—
—
—
—
—
—
—
—
—
—
6
17
60
643
—
—
—
—
—
—
fluticasone furoate; nasal
R01AD12 [21605053]
1.1e+00
-1.0e+50
—
—
—
-1.0e+50
3.4e-01
cases:10.61%
controls:3.79%
cases:0.00%
controls:2.27%
—
—
—
—
—
—
cases:0.00%
controls:2.62%
cases:10.91%
controls:8.01%
7
25
59
635
0
15
66
645
—
—
—
0
17
64
633
6
44
49
505
epinephrine; parenteral
C01CA24 [21600303]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
ciclesonide; nasal
R01AD13 [43534836]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
0
7
66
653
—
—
—
—
—
0
7
55
542
Limited function/disability (L)
L28 [2002000647]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
0
7
66
653
—
—
—
0
7
64
643
—
FEV1 --post bronchodilation
20155-8 [3023550]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Gas panel - Arterial blood
24336-0 [3019060]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.6e-01
3.5e-01
1.1e+00
—
1.1e+00
6.0e-01
2.9e-01
cases:30.30%
controls:26.97%
cases:25.76%
controls:19.70%
cases:7.58%
controls:2.73%
—
—
cases:9.23%
controls:3.33%
cases:31.25%
controls:20.00%
cases:38.18%
controls:31.69%
20
178
46
482
17
130
49
530
5
18
61
642
—
6
22
59
638
20
130
44
520
21
174
34
375
Rotator cuff syndrome
M75.1 [45596678]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
Simple examination of mouth
SAA01 [2001310274]
-3.5e-02
1.7e-01
—
—
-1.0e+50
—
-8.6e-02
cases:15.15%
controls:15.61%
cases:10.61%
controls:9.09%
—
—
—
—
cases:0.00%
controls:1.21%
—
—
cases:18.18%
controls:19.49%
10
103
56
557
7
60
59
600
—
—
0
8
65
652
—
10
107
45
442
Myopia
H52.1 [45533352]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Urinary tract infection, site not specified
N39.0 [45548665]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
66
648
—
—
—
—
—
—
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
—
clarithromycin; oral, parenteral
J01FA09 [21602977]
1.1e+00
-1.0e+50
—
—
—
—
—
cases:9.09%
controls:3.33%
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
6
22
60
638
0
5
66
655
—
—
—
—
—
fusidic acid
S01AA13 [21603564]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Skin infection other
S76 [2002001040]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Mucopurulent conjunctivitis
H10.0 [45596007]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Other primary gonarthrosis
M17.1 [45596493]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
—
0
10
66
650
—
—
—
—
—
General symptom/complaint other
A29 [2002000163]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
—
Laceration/cut
S18 [2002000983]
8.7e-01
1.0e+00
—
—
—
—
—
cases:12.12%
controls:5.45%
cases:7.58%
controls:2.88%
—
—
—
—
—
—
—
—
—
—
8
36
58
624
5
19
61
641
—
—
—
—
—
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
—
—
—
—
—
—
8.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:4.01%
—
—
—
—
—
—
5
22
50
527
Acute tubulo-interstitial nephritis
N10 [45543856]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
0
6
66
654
0
5
66
655
—
—
—
—
0
8
55
541
ofloxacin; oral, parenteral
J01MA01 [21603008]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
—
—
—
0
8
55
541
Dilated cardiomyopathy
I42.0 [45586581]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Examination for driving licence
Z02.4 [45552056]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:4.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:0.00%
controls:6.74%
0
29
66
631
—
—
—
—
0
6
64
644
0
37
55
512
Caries of cementum
K02.2 [45591568]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
1.3e-01
—
—
—
-1.0e+50
1.3e-01
3.6e-01
cases:10.61%
controls:9.39%
—
—
—
—
—
—
cases:0.00%
controls:1.52%
cases:7.81%
controls:6.92%
cases:18.18%
controls:13.48%
7
62
59
598
—
—
—
0
10
65
650
5
45
59
605
10
74
45
475
oxycodone and naloxone; oral
N02AA55 [21604265]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
0
12
66
648
—
—
—
—
—
0
9
55
540
Celiac disease serology panel - Serum
94494-2 [36660697]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Other complicated root filling
SGB30 [2001310390]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.82%
0
9
66
651
—
—
—
—
—
0
10
55
539
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.06%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
7
66
653
0
6
66
654
—
—
—
—
—
Recording of ECG
SPAT1097 [2001700198]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
cases:0.00%
controls:0.91%
—
—
—
—
—
0
5
64
645
0
5
55
544
Issue of repeat prescription
Z76.0 [45542456]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
0
7
66
653
—
—
—
—
—
Other signs and symptoms in breast
N64.5 [45539061]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Counselling, unspecified
Z71.9 [45561648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
0
5
64
645
—
simvastatin; oral
C10AA01 [21601856]
7.1e-01
7.4e-01
—
—
1.3e+00
7.5e-01
5.2e-01
cases:24.24%
controls:13.64%
cases:19.70%
controls:10.45%
—
—
—
—
cases:10.77%
controls:3.18%
cases:21.88%
controls:11.69%
cases:21.82%
controls:14.21%
16
90
50
570
13
69
53
591
—
—
7
21
58
639
14
76
50
574
12
78
43
471
fluvastatin; oral
C10AA04 [21601859]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
66
650
—
—
—
—
—
—
pseudoephedrine; oral
R01BA02 [21603210]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
66
653
—
—
—
—
—
—
Malignant otitis externa
H60.2 [45543099]
—
—
—
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
—
cases:95.45%
controls:0.00%
cases:33.85%
controls:0.00%
cases:20.31%
controls:0.00%
—
—
—
—
—
63
0
3
660
22
0
43
660
13
0
51
650
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
8.9e-01
—
—
—
—
—
6.8e-01
cases:9.09%
controls:3.94%
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:5.83%
6
26
60
634
—
—
—
—
—
6
32
49
517
prednisolone; oral, parenteral
H02AB06 [21602734]
5.7e-01
1.2e+00
—
—
-1.0e+50
—
3.3e-01
cases:13.64%
controls:8.18%
cases:9.09%
controls:2.88%
—
—
—
—
cases:0.00%
controls:0.76%
—
—
cases:12.73%
controls:9.47%
9
54
57
606
6
19
60
641
—
—
0
5
65
655
—
7
52
48
497
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
0
9
66
651
—
—
—
—
—
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
0
5
64
645
—
Two-surface restoration
SFA20 [2001310359]
4.3e-02
—
—
—
—
—
-1.4e-01
cases:12.12%
controls:11.67%
—
—
—
—
—
—
—
—
—
—
cases:12.73%
controls:14.39%
8
77
58
583
—
—
—
—
—
7
79
48
470
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
ranitidine; oral, parenteral
A02BA02 [21600083]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
0
5
66
655
—
—
—
—
0
10
55
539
Fall on same level involving ice and snow
W00 [45756242]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
66
653
—
—
—
—
—
—
bisoprolol; oral
C07AB07 [21601689]
2.9e-01
1.3e-01
—
—
—
8.4e-02
-1.1e-01
cases:18.18%
controls:14.24%
cases:13.64%
controls:12.12%
—
—
—
—
—
—
cases:14.06%
controls:13.08%
cases:14.55%
controls:16.03%
12
94
54
566
9
80
57
580
—
—
—
9
85
55
565
8
88
47
461
fluticasone furoate
R03BA09 [45893496]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
0
8
66
652
—
—
—
0
9
64
641
—
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
Musculoskeletal sympt/complt other
L29 [2002000648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Supplier / Service Provider
OMOP5117446 [33004]
-8.1e-01
—
-1.0e+50
—
—
—
—
cases:13.64%
controls:26.21%
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
9
173
57
487
—
0
6
66
654
—
—
—
—
Fracture of tooth, open
S02.51 [45755762]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
General Surgery
2 [38004447]
3.8e-01
1.4e+00
—
—
-1.0e+50
9.1e-01
6.4e-01
cases:25.76%
controls:19.24%
cases:15.15%
controls:4.39%
—
—
—
—
cases:0.00%
controls:0.91%
cases:14.06%
controls:6.15%
cases:25.45%
controls:15.30%
17
127
49
533
10
29
56
631
—
—
0
6
65
654
9
40
55
610
14
84
41
465
Atrial fibrillation/flutter
K78 [2002000605]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
—
insulin (human); parenteral
A10AD01 [21600729]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
0
8
65
652
—
—
Emergency treatment
SGA01 [2001310379]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
metoprolol; oral, parenteral
C07AB02 [21601684]
1.1e+00
1.3e+00
—
—
—
8.7e-01
9.0e-01
cases:12.12%
controls:4.39%
cases:12.12%
controls:3.79%
—
—
—
—
—
—
cases:9.38%
controls:4.15%
cases:10.91%
controls:4.74%
8
29
58
631
8
25
58
635
—
—
—
6
27
58
623
6
26
49
523
chloramphenicol
G01AA05 [21602367]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Therapeutic discussion
SPAT1240 [2001700341]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
0
6
64
644
—
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
—
—
—
—
—
—
9.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:4.74%
—
—
—
—
—
—
6
26
49
523
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
66
648
—
—
—
—
—
—
Cervicocranial syndrome
M53.0 [45562750]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
0
7
55
542
Fracture of lower end of radius
S52.5 [45573842]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
—
Primary arthrosis of other joints
M19.0 [45601353]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
0
7
55
542
Diabetes non-insulin dependent
T90 [2002001131]
7.8e-01
—
—
—
—
—
9.8e-01
cases:9.09%
controls:4.39%
—
—
—
—
—
—
—
—
—
—
cases:14.55%
controls:6.01%
6
29
60
631
—
—
—
—
—
8
33
47
516
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
4.3e-01
3.0e-01
—
—
1.9e+00
6.8e-01
2.8e-01
cases:19.70%
controls:13.79%
cases:13.64%
controls:10.45%
—
—
—
—
cases:9.23%
controls:1.52%
cases:15.63%
controls:8.62%
cases:20.00%
controls:15.85%
13
91
53
569
9
69
57
591
—
—
6
10
59
650
10
56
54
594
11
87
44
462
Gout, unspecified
M10.9 [45543454]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
Derangement of meniscus due to old tear or injury
M23.2 [45591779]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
—
Dry eye syndrome
H04.10 [2000502254]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
Supervision of normal pregnancy, unspecified
Z34.9 [45566420]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
5
55
544
fenofibrate; oral
C10AB05 [21601869]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:3.28%
—
—
—
—
—
—
6
18
49
531
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
0
9
55
540
Infiltration anesthesia
WX110 [2001310767]
2.8e-01
—
—
—
—
2.6e-01
-2.7e-01
cases:16.67%
controls:13.18%
—
—
—
—
—
—
—
—
cases:9.38%
controls:7.38%
cases:10.91%
controls:13.84%
11
87
55
573
—
—
—
—
6
48
58
602
6
76
49
473
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
doxycycline; oral, parenteral
J01AA02 [21602800]
5.5e-01
—
—
—
-1.0e+50
—
9.8e-01
cases:25.76%
controls:16.67%
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
cases:30.91%
controls:14.39%
17
110
49
550
—
—
—
0
5
65
655
—
17
79
38
470
Gynaecological examination (general)(routine)
Z01.4 [45542395]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
66
652
—
—
—
—
—
—
Gingivitis (chronic) NOS
K05.10 [2000502717]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:0.00%
controls:1.46%
—
—
—
—
—
0
6
64
644
0
8
55
541
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
66
654
—
—
—
—
—
—
semaglutide; oral, parenteral
A10BJ06 [1501778]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
0
5
64
645
—
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
66
651
—
—
—
—
—
—
Diabetes mellitus screening
171183004 [4064918]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
66
655
—
—
—
—
—
—
etoricoxib; oral
M01AH05 [21603996]
—
—
—
—
—
-1.0e+50
8.7e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:4.92%
cases:25.45%
controls:12.57%
—
—
—
—
—
0
32
64
618
14
69
41
480
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Place of Employment-Worksite
18 [581475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
6
55
543
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
0
6
66
654
—
—
—
—
0
9
55
540
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.82%
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
0
12
66
648
0
5
66
655
—
—
—
—
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
4.6e-01
8.9e-01
—
—
—
7.5e-01
6.7e-01
cases:10.61%
controls:6.97%
cases:9.09%
controls:3.94%
—
—
—
—
—
—
cases:7.81%
controls:3.85%
cases:14.55%
controls:8.01%
7
46
59
614
6
26
60
634
—
—
—
5
25
59
625
8
44
47
505

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
32
56
9.90
19.76
3.9
1.9
—
—
—
0
0
25
61
5.90
10.54
3.8
1.5
—
—
—
0
0
23
78
3.94
6.14
5.1
2.0
—
—
—
0
0
37
187
3.15
5.13
4.9
3.5
18.22
4.17
mg/mmol
1.03
26
119
47
274
3.32
5.07
10.6
6.6
0.05
0.04
e9/l
0.94
40
242
36
186
2.99
4.70
4.2
3.1
94.69
32.30
mg/l
0.68
27
121
47
282
3.16
4.67
10.8
6.6
1.88
1.83
e9/l
0.15
41
256
46
273
3.12
4.66
10.8
6.6
0.60
0.59
e9/l
0.15
40
240
47
283
3.14
4.62
11.1
6.9
0.17
0.19
e9/l
0.56
41
254
32
163
2.82
4.18
10.8
5.8
—
—
—
0
0
36
198
2.74
4.02
4.2
2.9
7.25
8.24
mmol/l
0.54
31
171
15
50
3.57
3.98
5.1
2.4
7.35
7.39
ph
—
8
29
29
146
2.72
3.81
10.4
4.3
—
—
—
0
0
11
26
4.84
3.70
4.8
2.8
24.21
25.16
mmol/l
0.27
11
26
15
53
3.35
3.63
5.2
2.5
5.79
5.68
kpa
0.19
15
53
22
98
2.84
3.62
10.6
3.1
400.43
169.85
ng/l
0.29
16
74
63
508
4.26
3.33
9.7
5.8
44.11
39.70
mmol/mol
1.78
56
479
11
30
4.17
3.26
4.4
2.6
118.55
135.17
g/l
1.40
11
30
10
26
4.32
3.13
10.2
4.2
—
—
—
0
0
6
9
7.18
2.93
1.2
1.3
—
—
—
0
0
13
48
3.11
2.91
18.2
5.9
—
—
—
0
0
18
82
2.63
2.78
6.4
1.9
11.29
15.65
umol/l
1.78
18
74
15
64
2.72
2.61
19.7
6.0
7.41
7.43
ph
—
8
37
9
26
3.83
2.59
21.7
7.8
24.34
24.02
mmol/l
—
9
26
9
26
3.83
2.59
8.2
3.1
36.99
36.94
°c
—
9
26
16
72
2.60
2.51
17.9
3.4
1.15
1.02
mmol/l
0.51
16
67
5
8
6.63
2.41
1.2
1.4
—
—
—
0
0
11
41
3.00
2.34
5.9
2.5
4.32
4.46
kpa
0.07
11
41
39
269
2.05
2.18
24.3
10.3
1.27
1.16
inr
0.60
33
231
8
25
3.48
2.17
5.4
2.3
1.19
1.21
%
—
8
25
8
25
3.48
2.17
5.3
2.2
0.75
0.62
%
—
8
25
60
502
2.66
2.11
6.7
5.3
1.90
1.94
mu/l
0.12
53
462
26
157
2.06
2.06
14.8
4.0
7.41
7.40
ph
0.36
20
114
11
45
2.72
2.05
20.2
6.1
1.21
1.30
mmol/l
0.23
11
45
14
67
2.37
1.92
2.4
1.7
—
—
—
0
0
34
233
1.92
1.84
25.9
11.9
0.00
0.00
e9/l
0.26
28
193
16
83
2.21
1.83
19.0
6.2
103.44
103.89
mmol/l
0.15
16
83
17
92
2.13
1.76
2.3
1.7
—
—
—
0
0
32
225
1.80
1.53
5.1
3.9
53.40
24.89
ng/l
0.71
25
157
62
547
2.51
1.49
7.3
5.6
2.47
2.70
mmol/l
1.06
56
512
13
68
2.13
1.45
7.5
1.9
20.59
26.52
%
1.10
13
62
63
565
2.56
1.42
33.7
13.8
—
—
—
0
0
14
77
2.03
1.38
8.1
1.8
2.22
2.39
g/l
0.56
14
69
60
525
2.21
1.36
6.0
4.8
6.32
5.93
mmol/l
1.39
54
488
32
234
1.69
1.29
2.4
2.0
—
—
—
0
0
45
361
1.73
1.28
8.4
4.3
—
27.00
—
0
7
17
103
1.87
1.28
8.3
3.7
0.78
0.80
mmol/l
0.33
17
98
6
25
2.53
1.27
4.3
2.0
24.27
24.30
mmol/l
—
6
25
22
145
1.76
1.27
5.6
3.0
—
—
—
0
0
18
112
1.83
1.25
2.1
1.8
—
—
—
0
0
17
104
1.85
1.24
1.4
1.3
12.04
14.35
iu/ml
—
5
32
8
38
2.25
1.23
26.3
7.2
0.64
0.68
%
—
8
38
8
38
2.25
1.23
26.4
7.3
93.04
94.72
%
—
8
38
31
228
1.66
1.20
2.8
2.0
85.59
91.38
pmol/l
0.36
21
122
8
39
2.19
1.20
26.3
7.1
1.74
1.52
%
—
8
39
32
239
1.64
1.16
11.1
4.3
33.97
36.05
g/l
1.75
32
232
19
123
1.76
1.16
1.5
1.4
2.47
2.20
g/l
0.29
11
74
34
258
1.64
1.16
5.1
2.5
—
—
estimate
—
0
0
22
149
1.70
1.15
1.9
1.7
15.93
20.86
nmol/l
0.93
17
127
23
158
1.69
1.14
7.1
2.9
0.15
0.33
e6/l
0.65
18
116
60
539
1.96
1.09
6.3
4.8
4.44
4.60
mmol/l
0.52
53
507
24
169
1.65
1.08
3.5
2.4
—
—
—
0
0
9
50
1.92
1.01
1.1
1.6
—
—
—
0
0
20
137
1.65
0.99
7.2
4.0
1.02
1.02
kg/l
0.02
13
95
10
55
1.96
0.98
1.1
1.2
—
—
—
0
0
8
43
1.97
0.91
1.8
1.6
67.20
73.20
e9/l
—
8
31
30
233
1.51
0.87
6.6
3.2
6.21
6.16
ph
0.10
14
144
8
46
1.84
0.86
5.0
3.6
—
—
—
0
0
24
178
1.54
0.85
8.2
6.6
—
—
—
0
0
6
32
1.96
0.84
30.2
7.2
23.67
23.74
mmol/l
—
6
32
19
134
1.58
0.83
9.4
3.8
94.26
91.78
%
0.20
19
134
24
179
1.53
0.83
7.0
3.2
15.44
21.66
e6/l
0.29
19
139
59
538
1.73
0.81
6.1
4.7
1.32
1.45
mmol/l
1.38
52
504
57
513
1.69
0.79
5.0
4.0
1.64
1.27
mmol/l
2.18
51
479
18
128
1.55
0.76
8.6
6.0
—
—
—
0
0
17
229
0.66
0.73
3.6
3.1
—
—
—
0
0
5
28
1.85
0.67
1.8
1.7
—
—
—
0
0
7
44
1.66
0.67
1.4
1.7
—
—
—
0
0
8
50
1.68
0.64
1.1
1.3
—
—
—
0
0
16
117
1.48
0.59
2.1
1.6
0.37
1.20
mg/l
2.77
11
107
10
67
1.58
0.53
1.2
1.2
—
—
—
0
0
35
303
1.32
0.47
6.9
3.7
0.00
0.00
estimate
—
6
65
35
304
1.31
0.46
6.9
3.6
0.00
0.00
estimate
—
7
71
0
19
0.00
0.39
0.0
1.5
—
293.48
—
0
11
34
299
1.27
0.39
6.9
3.5
0.00
0.00
estimate
—
7
70
12
90
1.40
0.39
1.4
1.3
0.98
10.73
u/ml
—
6
34
6
45
1.36
0.35
5.3
2.8
—
—
—
0
0
49
455
1.28
0.33
52.0
20.3
332.69
332.63
g/l
0.02
49
455
26
225
1.25
0.33
2.8
2.0
1.71
1.32
mmol/l
0.79
20
191
10
78
1.33
0.26
2.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
3.5
—
17.09
—
0
11
0
10
0.00
0.21
0.0
2.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
5
68
0.71
0.18
1.4
1.3
—
—
—
0
0
26
237
1.16
0.17
6.6
3.5
0.00
0.00
estimate
—
6
58
19
170
1.16
0.16
1.4
1.5
—
—
—
0
0
16
176
0.88
0.11
4.4
2.8
0.00
0.00
estimate
—
5
52
5
61
0.81
0.08
1.8
1.7
—
—
—
0
0
18
178
1.02
0.00
5.1
3.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
6.28
—
0
6
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
9.30
—
0
5
0
5
0.00
-0.00
0.0
12.0
—
0.61
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint H8_EXT_MALIGN and mortality.

Females

No data

Males

Parameter HR [95% CI] p-value
H8_EXT_MALIGN 1.384 [0.95, 2.01] 0.086
Birth year 0.989 [0.98, 1.0] 0.022

During the follow-up period (1.1.1998 — 31.12.2019), 73 out of 238 males with H8_EXT_MALIGN died.

Mortality risk

Mortality risk for people of age

years, who have H8_EXT_MALIGN.

N-year risk Females Males
1 No data 0.279%
5 No data 1.591%
10 No data 4.158%
15 No data 8.048%
20 No data 13.472%

Relationships between endpoints

↥

Index endpoint: H8_EXT_MALIGN – Malignant otitis externa

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data